Related Experiment Videos
Response to therapy as prognostic factor in chronic lymphocytic leukemia
Acta Haematologica
|January 1, 1980
Summary
Response to therapy significantly predicts survival in chronic lymphocytic leukemia (CLL) patients. Achieving complete or partial remission offers a better 5-year survival outlook than clinical staging alone.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy.
- Accurate prognostic indicators are crucial for guiding CLL treatment strategies.
Purpose of the Study:
- To evaluate the prognostic value of clinical staging versus treatment response in CLL patients.
- To determine which factor better predicts long-term survival.
Main Methods:
- Analysis of clinical staging and therapeutic response in 56 CLL patients.
- Actuarial survival curves were generated for different staging and response groups.
- Statistical significance was assessed using p-values.
Main Results:
- Therapeutic response significantly impacted survival (p < 0.001).
- Patients achieving complete or partial remission had a 72% 5-year survival, versus 20% for those with failure or only improvement.
- Clinical staging showed a non-significant trend (p = 0.08), with 59% 5-year survival for Stages O-II and 27% for Stages III-IV.
Conclusions:
- Treatment response is a superior predictor of 5-year survival in CLL compared to clinical staging.
- Optimizing therapy to achieve remission is critical for improving patient outcomes in CLL.